高级检索
    周彩存, 费世江. 有EGFR突变的非小细胞肺癌患者吉非替尼与含铂双药化疗疗效比较[J]. 循证医学, 2011, 11(1): 28-30. DOI: 10.3969/j.issn.1671-5144.2011.01.016
    引用本文: 周彩存, 费世江. 有EGFR突变的非小细胞肺癌患者吉非替尼与含铂双药化疗疗效比较[J]. 循证医学, 2011, 11(1): 28-30. DOI: 10.3969/j.issn.1671-5144.2011.01.016
    shu
    ZHOU Cai-cun, FEI Shi-jiang. The Efficacy of Gefitinib versus Platinum Doublet Chemotherapy in Patients with Non-Small Cell Lung Cancer Harbouring Mutations of the Epidermal Growth Factor Receptor[J]. Journal of Evidence-Based Medicine, 2011, 11(1): 28-30. DOI: 10.3969/j.issn.1671-5144.2011.01.016
    Citation: ZHOU Cai-cun, FEI Shi-jiang. The Efficacy of Gefitinib versus Platinum Doublet Chemotherapy in Patients with Non-Small Cell Lung Cancer Harbouring Mutations of the Epidermal Growth Factor Receptor[J]. Journal of Evidence-Based Medicine, 2011, 11(1): 28-30. DOI: 10.3969/j.issn.1671-5144.2011.01.016
    shu

    有EGFR突变的非小细胞肺癌患者吉非替尼与含铂双药化疗疗效比较

    The Efficacy of Gefitinib versus Platinum Doublet Chemotherapy in Patients with Non-Small Cell Lung Cancer Harbouring Mutations of the Epidermal Growth Factor Receptor

      摘要
    • 摘要: EGFR-TKI吉非替尼和厄洛替尼均已被批准用于晚期NSCLC的二线或三线治疗, 取得了良好的疗效, 而且与化疗相比有较好的安全性与生活质量。一些回顾性研究及前瞻性研究均提示EGFR突变是EGFR-TKI疗效重要预测因子, EGFR-TKI在EGFR突变NSCLC患者中的疗效显著优于无突变患者, 也显著优于常规化疗。

       

      • HTML全文
      • 参考文献(0)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回